Prostate Cancer, Prostate Cancer Metastatic
Conditions
Keywords
PET/CT, prostate cancer, Gallium-68, PSMA-11
Brief summary
To goal of this research is to assess the ability of Gallium-68 (68Ga) Prostate-Specific Membrane Antigen-11 (PSMA-11) positron emission tomography/computed tomography (PET/CT) to increase diagnostic accuracy in localizing primary and metastatic lesions in patients with suspected prostate cancer and elevated Prostate Imaging Reporting and Data System (PI-RADS) scores and Prostate-Specific Antigen (PSA).
Detailed description
This study is designed to evaluate the added value of 68Ga PSMA-11 PET/CT for detection of additional primary prostate cancer lesions compared to multiparametric magnetic resonance imaging (mpMRI) in a group of patients with elevated PI-RADS scores and PSA. We propose that the addition of early dynamic 68Ga PSMA-11 PET/CT imaging to the more usual delayed imaging will enhance detection of primary lesions and additional lesions not detected on the mpMRI. In addition, the dynamic imaging will allow us to evaluate the kinetics of uptake in the prostate gland. It is possible that even in the absence of focal uptake, hyperemia of the gland could indicate the presence of an occult primary. A second purpose of this research is to examine the value of 68Ga PSMA-11 PET/CT in this same group of patients in detecting metastatic disease at initial staging in comparison with current standard of care imaging such as computed tomography (CT) and magnetic resonance imaging (MRI).
Interventions
Injection of 68Ga PSMA-11
PET/CT scan after 68Ga PSMA-11 injection
Sponsors
Dana Mathews
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Unblinded, single arm imaging study
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with suspected prostate cancer (e.g., abnormal digital rectal exam, elevated and/or rising PSA) as determined by referring physician * Patients must have had a diagnostic, standard of care mpMRI of the prostate with at least one lesion with a PI-RADS v2.1 score ≥ 4 * In men with PI-RADS v2.1 score 4, PSA should be ≥ 10 ng/mL. In men with at least one PI-RADS v2.1 score 5 lesion, there is no restriction on PSA level. * Patients must be scheduled for biopsy or radical prostatectomy * Patients should not have had any type of curative or palliative therapy for prostate cancer before enrolling in the study * Patients must be medically stable as judged by the patient's physician * Patients must be able to lie still for a total of 60 minutes for the PET/CT scans * Ability to understand and the willingness to sign a written informed consent
Exclusion criteria
* Patients who have had a prior prostatectomy or radiotherapy for prostate cancer cannot participate in the study * Patients who have had a prior biopsy for prostate cancer cannot participate in the study * Patients who have been treated for cancers other than skin cancers * Subjects may not be receiving any other investigational agents for the treatment of the cancer under study * Patients may not weigh more than the maximum weight limit for the PET/CT scanner table (\>200 kilograms or 440 pounds) * History of allergic reactions attributed to compounds of similar chemical or biologic composition to 68Ga PSMA-11 or other agents used in the study such as gadolinium-based intravenous contrast agent used during the mpMRI * Prior transurethral resection of the prostate (TURP)/benign prostatic hyperplasia (BPH) procedures, including steam/laser therapies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging | During PET/CT imaging, up to 2 hours | Number of primary prostate lesions will be detected using early dynamic 68Ga-PSMA-11 PET/CT imaging. PSMA is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protein. |
| Number of Primary Prostate Lesions Detected by mpMRI | During mpMRI, up to 2 hours | Number of primary prostate lesions will be detected by using mpMRI. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Sites of Metastatic Prostate Lesions Detected on 68Ga-PSMA-11 PET/CT | During PET/CT imaging, up to 2 hours | Number of sites of metastatic prostate lesions will be detected using 68Ga-PSMA-11 PET/CT. PSMA is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protein. |
| Number of Sites of Metastatic Prostate Lesions Detected by Current Standard of Care Imaging (CT/MRI) | During CT/MRI imaging, up to 2 hours | Patients with metastatic prostate lesions were imaged using current standard of care imaging (CT/MRI). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Patients With Suspected Prostate Cancer Patients with suspected prostate cancer who have at least one PI-RADS 5 lesion, or at least one PI-RADS 4 lesion and PSA ≥10 nanograms/milliliter (ng/mL), on standard of care mpMRI of the prostate, who are scheduled for biopsy or radical prostatectomy
68Ga PSMA-11 injection: Injection of 68Ga PSMA-11
Positron Emission Tomography/Computed Tomography: PET/CT scan after 68Ga PSMA-11 injection | 20 |
| Total | 20 |
Baseline characteristics
| Characteristic | Patients With Suspected Prostate Cancer |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 11 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants |
| Age, Continuous | 64.85 years STANDARD_DEVIATION 8.54 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 18 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 18 Participants |
| Region of Enrollment United States | 20 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 20 |
| other Total, other adverse events | 6 / 20 |
| serious Total, serious adverse events | 0 / 20 |
Outcome results
Primary
Number of Primary Prostate Lesions Detected by mpMRI
Number of primary prostate lesions will be detected by using mpMRI.
Time frame: During mpMRI, up to 2 hours
Population: All patients who received a 68Ga-PSMA-11 injection for diagnosis of primary prostate cancer with PET/CT imaging.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients With Suspected Prostate Cancer | Number of Primary Prostate Lesions Detected by mpMRI | 37 lesions |
Primary
Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging
Number of primary prostate lesions will be detected using early dynamic 68Ga-PSMA-11 PET/CT imaging. PSMA is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protein.
Time frame: During PET/CT imaging, up to 2 hours
Population: All patients who received a 68Ga-PSMA-11 injection for diagnosis of primary prostate cancer with PET/CT imaging.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients With Suspected Prostate Cancer | Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging | 24 lesions |
Secondary
Number of Sites of Metastatic Prostate Lesions Detected by Current Standard of Care Imaging (CT/MRI)
Patients with metastatic prostate lesions were imaged using current standard of care imaging (CT/MRI).
Time frame: During CT/MRI imaging, up to 2 hours
Population: All patients who received a 68Ga-PSMA-11 injection for diagnosis of primary prostate cancer with PET/CT imaging
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients With Suspected Prostate Cancer | Number of Sites of Metastatic Prostate Lesions Detected by Current Standard of Care Imaging (CT/MRI) | 5 sites |
Secondary
Number of Sites of Metastatic Prostate Lesions Detected on 68Ga-PSMA-11 PET/CT
Number of sites of metastatic prostate lesions will be detected using 68Ga-PSMA-11 PET/CT. PSMA is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protein.
Time frame: During PET/CT imaging, up to 2 hours
Population: 19 patients completed 68Ga-PSMA-11 PET/CT imaging as part of the study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients With Suspected Prostate Cancer | Number of Sites of Metastatic Prostate Lesions Detected on 68Ga-PSMA-11 PET/CT | 7 sites |